Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jade Ghosn

Showing results (121-130 of 267) with videos related to

Pageof 27
Sort By:
AIDS (London, England)|June 3, 2009
Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trialCathia Soulié, Lambert Assoumou, Jade Ghosn, et al.
The Journal of Antimicrobial Chemotherapy|March 18, 2008
Absence of HIV-1 shedding in male genital tract after 1 year of first-line lopinavir/ritonavir alone or in combination with zidovudine/lamivudineJade Ghosn, Marie-Laure Chaix, Gilles Peytavin, et al.
The Journal of Antimicrobial Chemotherapy|May 17, 2024
Incidence and factors associated with PrEP discontinuation in FranceNina Garofoli, Martin Siguier, Olivier Robineau, et al.
Open Forum Infectious Diseases|November 3, 2022
A Healthcare-Associated Infection With Monkeypox Virus of a Healthcare Worker During the 2022 OutbreakDiane Le Pluart, Mirabelle Ruyer-Thompson, Valentine Marie Ferré, et al.
Clinical and Experimental Dermatology|June 27, 2025
Detection of alpha-HPV types in cutaneous squamous cell carcinoma associated with markers of carcinogenesis: a retrospective studyFlorence Brunet-Possenti, Morgane Weiss, Jean-Luc Prétet, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|July 3, 2026
Overlooked risk factors for European autochthonous strongyloidiasis, Paris, FranceBenoît Heid-Picard, Marion Parisey, Jade Ghosn, et al.
Plos One|November 19, 2013
Symptomatic illness and low CD4 cell count at HIV seroconversion as markers of severe primary HIV infectionSara Lodi, Martin Fisher, Andrew Phillips, et al.
The Journal of Antimicrobial Chemotherapy|September 30, 2017
Penetration and antiviral efficacy of total and unbound maraviroc, raltegravir and rilpivirine in both female and male genital fluids from HIV-positive patients receiving regimens containing these antiretroviralsMinh P Lê, Linda Belarbi, Marie-Laure Chaix, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 19, 2012
Maraviroc intensification of stable antiviral therapy in HIV-1-infected patients with poor immune restoration: MARIMUNO-ANRS 145 studyLise Cuzin, Selma Trabelsi, Pierre Delobel, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 5, 2015
Impact of the Timing of Initiation of Antiretroviral Therapy During Primary HIV-1 Infection on the Decay of Cell-Associated HIV-DNAMoussa Laanani, Jade Ghosn, Asma Essat, et al.
Pageof 27

Showing results (121-130 of 267) with videos related to

Sort By:
Pageof 27
AIDS (London, England)|June 3, 2009
Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trialCathia Soulié, Lambert Assoumou, Jade Ghosn, et al.
The Journal of Antimicrobial Chemotherapy|March 18, 2008
Absence of HIV-1 shedding in male genital tract after 1 year of first-line lopinavir/ritonavir alone or in combination with zidovudine/lamivudineJade Ghosn, Marie-Laure Chaix, Gilles Peytavin, et al.
The Journal of Antimicrobial Chemotherapy|May 17, 2024
Incidence and factors associated with PrEP discontinuation in FranceNina Garofoli, Martin Siguier, Olivier Robineau, et al.
Open Forum Infectious Diseases|November 3, 2022
A Healthcare-Associated Infection With Monkeypox Virus of a Healthcare Worker During the 2022 OutbreakDiane Le Pluart, Mirabelle Ruyer-Thompson, Valentine Marie Ferré, et al.
Clinical and Experimental Dermatology|June 27, 2025
Detection of alpha-HPV types in cutaneous squamous cell carcinoma associated with markers of carcinogenesis: a retrospective studyFlorence Brunet-Possenti, Morgane Weiss, Jean-Luc Prétet, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|July 3, 2026
Overlooked risk factors for European autochthonous strongyloidiasis, Paris, FranceBenoît Heid-Picard, Marion Parisey, Jade Ghosn, et al.
Plos One|November 19, 2013
Symptomatic illness and low CD4 cell count at HIV seroconversion as markers of severe primary HIV infectionSara Lodi, Martin Fisher, Andrew Phillips, et al.
The Journal of Antimicrobial Chemotherapy|September 30, 2017
Penetration and antiviral efficacy of total and unbound maraviroc, raltegravir and rilpivirine in both female and male genital fluids from HIV-positive patients receiving regimens containing these antiretroviralsMinh P Lê, Linda Belarbi, Marie-Laure Chaix, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 19, 2012
Maraviroc intensification of stable antiviral therapy in HIV-1-infected patients with poor immune restoration: MARIMUNO-ANRS 145 studyLise Cuzin, Selma Trabelsi, Pierre Delobel, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 5, 2015
Impact of the Timing of Initiation of Antiretroviral Therapy During Primary HIV-1 Infection on the Decay of Cell-Associated HIV-DNAMoussa Laanani, Jade Ghosn, Asma Essat, et al.
Pageof 27